Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $177.00 by Analysts at Royal Bank Of Canada

Neurocrine Biosciences (NASDAQ:NBIX) had its target price lowered by Royal Bank Of Canada from $180.00 to $177.00 in a research note issued to investors on Thursday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Several other research firms also recently issued reports on NBIX. Zacks Research downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. JPMorgan Chase & Co. lowered their target price on Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Monday, January 12th. Needham & Company LLC reduced their price target on Neurocrine Biosciences from $187.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday. Morgan Stanley restated an “equal weight” rating and set a $175.00 price objective (up from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. Finally, Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, February 8th. Fifteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $177.56.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $123.10 on Thursday. The business has a 50 day moving average of $140.77 and a 200-day moving average of $140.46. The company has a market capitalization of $12.27 billion, a P/E ratio of 26.42, a P/E/G ratio of 0.64 and a beta of 0.31. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $160.18.

Insider Transactions at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer owned 140,407 shares of the company’s stock, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Leslie V. Norwalk sold 5,000 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $152.23, for a total transaction of $761,150.00. Following the transaction, the director owned 7,429 shares in the company, valued at approximately $1,130,916.67. The trade was a 40.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,966 shares of company stock valued at $8,625,166 in the last 90 days. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Assetmark Inc. lifted its holdings in Neurocrine Biosciences by 10.8% during the 2nd quarter. Assetmark Inc. now owns 21,001 shares of the company’s stock worth $2,640,000 after purchasing an additional 2,045 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Neurocrine Biosciences by 87.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 125,162 shares of the company’s stock valued at $15,732,000 after buying an additional 58,562 shares during the period. Saturn V Capital Management LP bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $7,313,000. Capital Fund Management S.A. lifted its holdings in shares of Neurocrine Biosciences by 15.9% in the second quarter. Capital Fund Management S.A. now owns 203,628 shares of the company’s stock worth $25,594,000 after buying an additional 27,987 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB boosted its position in shares of Neurocrine Biosciences by 66.1% in the second quarter. Rhenman & Partners Asset Management AB now owns 149,217 shares of the company’s stock valued at $18,755,000 after acquiring an additional 59,400 shares during the period. 92.59% of the stock is owned by institutional investors.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.